These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment

UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug

Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest

Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says

Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug

EU medicines regulator rejects Eisai-Biogen Alzheimer's drug

Japan's Eisai developing dementia drug for US market, Nikkei reports

Eisai and Biogen launch Alzheimer's drug Leqembi in China

EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes

China approves Alzheimer's treatment Leqembi by Eisai and Biogen

Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial

Merck-Eisai's cancer therapy combo fails in late-stage study

More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study

Japan approves Alzheimer treatment Leqembi by Eisai and Biogen

Merck and Eisai say two lung-cancer trials failed to meet their main goals

Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals

Merck, Eisai discontinue late-stage study for cancer therapy

More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning

US FDA grants standard approval of Eisai/Biogen Alzheimer's drug

European Alzheimer's experts unconvinced by new Eisai, Biogen drug

FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen

Merck and Eisai report disappointing results from trials of combination treatment for melanoma and colorectal cancer

FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July

Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage

Eisai files for full FDA approval for Alzheimer's drug Leqembi

FDA approves Biogen, Eisai Alzheimer's drug

FDA approves treatment for people with mild forms of Alzheimer's

FDA Approves Eisai and Biogen's New Alzheimer's Therapy